![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BeiGene Touts Topline Phase 3 Data for Nasopharyngeal Cancer Therapy
BeiGene Touts Topline Phase 3 Data for Nasopharyngeal Cancer Therapy
![BeiGene logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/BeiGene-logo.gif?t=1621632182&width=430)
Chinese drugmaker BeiGene said its anti-PD-1 antibody tislelizumab combined with chemotherapy improved survival for patients with recurrent or metastatic nasopharyngeal cancer in a late-stage trial.
In the 263-participant phase 3 trial, tislelizumab plus chemotherapy was shown to be more effective than chemotherapy alone for improving progression-free survival, the company said.
Tislelizumab is already approved in China for treating advanced squamous nonsmall-cell lung cancer in combination with chemotherapy and conditionally approved for patients with Hodgkin’s lymphoma and metastatic bladder cancer with high PD-L1 expression.
Upcoming Events
-
21Oct